Glaukos Corporation Share Price

Equities

GKOS

US3773221029

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 21:00:02 19/07/2024 BST 5-day change 1st Jan Change
120.7 USD +1.70% Intraday chart for Glaukos Corporation -0.30% +51.88%
Sales 2024 * 363M 28.12B Sales 2025 * 452M 34.99B Capitalization 6.59B 511B
Net income 2024 * -128M -9.91B Net income 2025 * -79M -6.12B EV / Sales 2024 * 18.4 x
Net Debt 2024 * 95.04M 7.36B Net Debt 2025 * 130M 10.1B EV / Sales 2025 * 14.9 x
P/E ratio 2024 *
-47.6 x
P/E ratio 2025 *
-78 x
Employees 907
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.47%
More Fundamentals * Estimated data
Dynamic Chart
1 day+1.70%
1 week-0.30%
Current month+2.01%
1 month+8.12%
3 months+25.11%
6 months+32.25%
Current year+51.88%
More quotes
1 week
112.88
Extreme 112.88
126.96
1 month
111.43
Extreme 111.43
126.96
Current year
74.75
Extreme 74.745
126.96
1 year
59.22
Extreme 59.22
126.96
3 years
33.33
Extreme 33.33
126.96
5 years
23.31
Extreme 23.31
126.96
10 years
14.25
Extreme 14.25
126.96
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 31/12/00
Director of Finance/CFO 54 30/06/16
President 48 04/05/17
Members of the board TitleAgeSince
Director/Board Member 65 31/12/06
Director/Board Member 69 30/06/14
Director/Board Member 55 30/06/14
More insiders
Date Price Change Volume
19/07/24 120.7 +1.70% 406,245
18/07/24 118.7 -4.39% 1,044,183
17/07/24 124.2 -1.22% 575,026
16/07/24 125.7 +2.05% 774,828
15/07/24 123.2 +1.72% 399,328

Delayed Quote Nyse, July 19, 2024 at 09:00 pm

More quotes
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
120.7 USD
Average target price
123.3 USD
Spread / Average Target
+2.16%
Consensus